206 related articles for article (PubMed ID: 7705708)
1. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.
Domagala W; Markiewski M; Harezga B; Dukowicz A; Osborn M
Clin Cancer Res; 1996 Jan; 2(1):147-54. PubMed ID: 9816101
[TBL] [Abstract][Full Text] [Related]
5. [Immunohistochemical detection and prognostic significance of p53 in the primary tumor of breast carcinoma patients].
Beck T; Weller E; Weikel W; Brumm C; Wilkens C; Knapstein PG
Geburtshilfe Frauenheilkd; 1995 May; 55(5):252-7. PubMed ID: 7607381
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival.
Hanzal E; Gitsch G; Kohlberger P; Dadak C; Miechowiecka N; Breitenecker G
Anticancer Res; 1992; 12(6B):2325-9. PubMed ID: 1295480
[TBL] [Abstract][Full Text] [Related]
7. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
10. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
11. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer.
Elledge RM; Clark GM; Fuqua SA; Yu YY; Allred DC
Cancer Res; 1994 Jul; 54(14):3752-7. PubMed ID: 8033095
[TBL] [Abstract][Full Text] [Related]
12. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
13. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
Lopes A; Bezerra AL; Pinto CA; Serrano SV; de MellO CA; Villa LL
J Urol; 2002 Jul; 168(1):81-6. PubMed ID: 12050497
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemical analysis of p53 and c-erbB-2 in breast cancer].
Castiglioni T; Elsner B; Curutchet HP; Montesinos M; Debonis D
Medicina (B Aires); 1995; 55(5 Pt 1):415-20. PubMed ID: 8728771
[TBL] [Abstract][Full Text] [Related]
17. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
Lavertu P; Adelstein DJ; Myles J; Secic M
Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
[TBL] [Abstract][Full Text] [Related]
18. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
Meenakshi A; Manoharan V
Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
[TBL] [Abstract][Full Text] [Related]
19. Incidence of apoptosis, cell proliferation and P53 expression in renal cell carcinomas.
Tannapfel A; Hahn HA; Katalinic A; Fietkau RJ; Kühn R; Wittekind CW
Anticancer Res; 1997; 17(2A):1155-62. PubMed ID: 9137464
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma.
Visscher DW; Sarkar F; Tabaczka P; Crissman J
Mod Pathol; 1996 Jun; 9(6):642-6. PubMed ID: 8782201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
